Trinity Biotech Return on Tangible Equity 2010-2024 | TRIB
Current and historical return on tangible equity values for Trinity Biotech (TRIB) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Trinity Biotech Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-09-30 | $-0.02B | $-0.07B | 34.29% |
| 2024-06-30 | $-0.02B | $-0.07B | 44.66% |
| 2024-03-31 | $-0.02B | $-0.06B | 54.32% |
| 2023-12-31 | $-0.03B | $-0.04B | 77.52% |
| 2023-09-30 | $-0.03B | $-0.03B | 92.06% |
| 2023-06-30 | $-0.03B | $-0.03B | 100.81% |
| 2023-03-31 | $-0.04B | $-0.03B | 117.65% |
| 2022-12-31 | $-0.04B | $-0.04B | 121.48% |
| 2022-09-30 | $-0.03B | $-0.03B | 95.52% |
| 2022-06-30 | $-0.02B | $-0.02B | 64.23% |
| 2022-03-31 | $-0.01B | $-0.04B | 35.37% |
| 2021-12-31 | $0.00B | $-0.04B | -2.90% |
| 2021-09-30 | $-0.01B | $-0.03B | 23.19% |
| 2021-06-30 | $-0.00B | $-0.03B | 5.52% |
| 2021-03-31 | $-0.00B | $-0.04B | 5.03% |
| 2020-12-31 | $-0.01B | $-0.04B | 14.20% |
| 2020-09-30 | $-0.02B | $-0.04B | 44.19% |
| 2020-06-30 | $-0.03B | $-0.05B | 69.33% |
| 2020-03-31 | $-0.03B | $-0.05B | 100.00% |
| 2019-12-31 | $-0.03B | $-0.04B | 131.76% |
| 2019-09-30 | $-0.03B | $-0.02B | 210.91% |
| 2019-06-30 | $-0.03B | $-0.02B | 294.74% |
| 2019-03-31 | $-0.02B | $-0.01B | 382.61% |
| 2018-12-31 | $-0.02B | $-0.01B | 628.57% |
| 2018-09-30 | $-0.04B | $-0.00B | 3280.00% |
| 2018-06-30 | $-0.04B | $-0.00B | -1527.27% |
| 2018-03-31 | $-0.04B | $-0.00B | -579.31% |
| 2017-12-31 | $-0.04B | $0.00B | -328.00% |
| 2017-09-30 | $-0.10B | $0.01B | -557.75% |
| 2017-06-30 | $-0.10B | $0.02B | -425.53% |
| 2017-03-31 | $-0.10B | $0.02B | -330.00% |
| 2016-12-31 | $-0.10B | $0.02B | -274.83% |
| 2016-09-30 | $0.00B | $0.04B | 6.70% |
| 2016-06-30 | $0.02B | $0.04B | 32.49% |
| 2016-03-31 | $0.02B | $0.05B | 32.69% |
| 2015-12-31 | $0.02B | $0.05B | 40.93% |
| 2015-09-30 | $0.02B | $0.06B | 42.99% |
| 2015-06-30 | $0.02B | $0.05B | 28.30% |
| 2015-03-31 | $0.02B | $0.05B | 29.49% |
| 2014-12-31 | $0.02B | $0.05B | 29.36% |
| 2014-09-30 | $0.02B | $0.05B | 30.91% |
| 2014-06-30 | $0.01B | $0.06B | 18.52% |
| 2014-03-31 | $0.01B | $0.06B | 15.87% |
| 2013-12-31 | $0.01B | $0.05B | 13.56% |
| 2013-09-30 | $0.01B | $0.05B | 10.68% |
| 2013-06-30 | $0.02B | $0.09B | 16.54% |
| 2013-03-31 | $0.02B | $0.10B | 16.41% |
| 2012-12-31 | $0.02B | $0.10B | 16.37% |
| 2012-09-30 | $0.02B | $0.10B | 15.96% |
| 2012-06-30 | $0.02B | $0.10B | 15.72% |
| 2012-03-31 | $0.02B | $0.10B | 15.42% |
| 2011-12-31 | $0.02B | $0.11B | 15.24% |
| 2011-09-30 | $0.02B | $0.11B | 15.31% |
| 2011-06-30 | $0.02B | $0.11B | 14.49% |
| 2011-03-31 | $0.06B | $0.10B | 60.93% |
| 2010-12-31 | $0.06B | $0.10B | 71.98% |
| 2010-09-30 | $0.06B | $0.10B | 88.89% |
| 2010-06-30 | $0.06B | $0.10B | 118.81% |
| 2010-03-31 | $0.01B | $0.04B | 35.56% |
| 2009-12-31 | $0.01B | $0.04B | 37.80% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.006B | $0.057B |
| Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $198.127B | 25.27 |
| Stryker (SYK) | United States | $138.991B | 31.32 |
| Boston Scientific (BSX) | United States | $131.097B | 37.69 |
| EssilorLuxottica (ESLOY) | France | $109.895B | 0.00 |
| Medtronic (MDT) | Ireland | $103.904B | 15.43 |
| Haleon (HLN) | United Kingdom | $43.864B | 28.50 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.859B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $36.052B | 18.70 |
| ResMed (RMD) | United States | $34.830B | 28.62 |
| Terumo (TRUMY) | Japan | $28.875B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $23.602B | 18.07 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.325B | 13.58 |
| Insulet (PODD) | United States | $18.698B | 74.46 |
| Baxter (BAX) | United States | $15.062B | 9.80 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.781B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.800B | 39.43 |
| Bio-Rad Laboratories (BIO) | United States | $9.168B | 31.16 |
| Demant (WILYY) | Denmark | $7.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.208B | 14.42 |
| Prestige Consumer Healthcare (PBH) | United States | $3.889B | 19.34 |
| ICU Medical (ICUI) | United States | $3.840B | 36.56 |
| Haemonetics (HAE) | United States | $3.789B | 18.49 |
| Perrigo (PRGO) | Ireland | $3.513B | 10.34 |
| Envista Holdings (NVST) | United States | $3.218B | 23.97 |
| QuidelOrtho (QDEL) | United States | $3.016B | 19.41 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.864B | 18.36 |
| Neogen (NEOG) | United States | $2.609B | 30.10 |
| LeMaitre Vascular (LMAT) | United States | $2.071B | 50.34 |
| Green Thumb Industries (GTBIF) | United States | $1.678B | 29.37 |
| AtriCure (ATRC) | United States | $1.498B | 0.00 |
| InMode (INMD) | Israel | $1.434B | 8.63 |
| AdaptHealth (AHCO) | United States | $1.383B | 9.88 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.356B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.271B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.968B | 0.00 |
| Owens & Minor (OMI) | United States | $0.965B | 7.54 |
| CeriBell (CBLL) | United States | $0.964B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.879B | 15.49 |
| Evolus (EOLS) | United States | $0.690B | 0.00 |
| Omeros (OMER) | United States | $0.597B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.594B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.584B | 25.75 |
| Surmodics (SRDX) | United States | $0.568B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.452B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.439B | 0.00 |
| Quanterix (QTRX) | United States | $0.403B | 0.00 |
| ZimVie (ZIMV) | United States | $0.375B | 31.63 |
| Biote (BTMD) | United States | $0.331B | 7.26 |
| Valneva SE (VALN) | France | $0.324B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.311B | 29.56 |
| Canopy Growth (CGC) | Canada | $0.308B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.294B | 0.00 |
| Cerus (CERS) | United States | $0.293B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.272B | 18.20 |
| Zynex (ZYXI) | United States | $0.263B | 55.00 |
| High Tide (HITI) | Canada | $0.242B | 100.33 |
| Aurora Cannabis (ACB) | Canada | $0.234B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.207B | 14.29 |
| Sanuwave Health (SNWV) | United States | $0.201B | 2.82 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.197B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.190B | 0.00 |
| Brainsway (BWAY) | Israel | $0.174B | 92.40 |
| FitLife Brands (FTLF) | United States | $0.145B | 18.17 |
| Jin Medical (ZJYL) | China | $0.133B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.124B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.107B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.81 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.096B | 0.00 |
| Veru (VERU) | United States | $0.095B | 0.00 |
| Exagen (XGN) | United States | $0.091B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.067B | 34.67 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.056B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.051B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.048B | 0.00 |
| Safety Shot (SHOT) | United States | $0.044B | 0.00 |
| ImmuCell (ICCC) | United States | $0.039B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.74 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |